Biomea Fusion, Inc.

Equities

BMEA

US09077A1060

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 13/07/2024 am IST 5-day change 1st Jan Change
5.29 USD +6.65% Intraday chart for Biomea Fusion, Inc. +25.06% -63.57%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from S&P Biotechnology Select Industry Index CI
Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Top Midday Decliners MT
Piper Sandler Adjusts Price Target on Biomea Fusion to $10 From $45, Maintains Overweight Rating MT
Scotiabank Cuts Price Target on Biomea Fusion to $21 From $41, Maintains Sector Outperform Rating MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday MT
Jobs Growth Tops Forecasts as US Equity Futures Post Narrow Losses Pre-Bell MT
Top Premarket Decliners MT
Barclays Downgrades Biomea Fusion to Equalweight From Overweight, Adjusts Price Target to $5 From $30 MT
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold; Shares Plummet Premarket MT
Biomea Fusion Down 61% on Clinical Hold for Diabetes Drug DJ
Biomea Reports Diabetes Drug Candidate Placed on Clinical Hold MT
U.S. FDA places hold on Biomea's diabetes trial RE
Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold CI
Biomea Fusion Completes Enrollment of First 3 Dose Expansion Arms of Diabetes Trial MT
Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes CI
Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating MT
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Powell Awaited -2- DJ
Biomea Fusion Shares Decline Following JPMorgan Downgrade MT
JPMorgan Downgrades Biomea Fusion to Neutral From Overweight, Adjusts Price Target to $14 From $51 MT
Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112) CI
Biomea Fusion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Tech in Focus on -2- DJ
Chart Biomea Fusion, Inc.
More charts
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.29 USD
Average target price
24.43 USD
Spread / Average Target
+361.79%
Consensus
  1. Stock Market
  2. Equities
  3. BMEA Stock
  4. News Biomea Fusion, Inc.
  5. Oppenheimer Adjusts Biomea Fusion Price Target to $60 From $70, Maintains Outperform Rating